About the
Cardiometabolic
Center Alliance
About Us
Saint Luke’s Micheal & Marlys Haverty Cardiometabolic Center of Excellence was launched in November 2018. The Cardiometabolic Center’s dedicated, multidisciplinary team developed a novel approach to treating those living with Type 2 diabetes or prediabetes along with related cardiovascular comorbidities, providing a comprehensive, team-based model of care specifically tailored to each patient.
To measure the effectiveness of this new model of care delivery, patient outcomes and treatment patterns were collected in a dedicated registry. Upon review of this data, it was clear that approaching care in a coordinated, multidisciplinary, and comprehensive manner resulted in substantial differences in patient outcomes.
Expanding this clinical model helps those living with or at risk for cardiometabolic conditions improve their health and prevent complications, as well as assists providers and health care organizations with managing the increasing strain of caring for this complex patient population.
The Alliance is a national collaborative of health care organizations committed to improving the quality of care and outcomes in those living with cardiometabolic disease. Across its aligned member sites, care is delivered via a patient-centered, team-based approach with the support of validated protocols, standard operating procedures, and ongoing program support. Members contribute to the Alliance’s Patient Registry for the purpose of rapid-cycle process improvement, as well as potential clinical research activities.
Since the formation of the Alliance, more than 18 national organizations have recognized the benefits and become members. Alliance membership continues to increase and includes large academic health systems, community-based health systems, rural-based health systems as well as potential international members.
The overarching goals of the Alliance include:
- Improving quality of care and outcomes for individuals with cardiometabolic disease
- Creating platforms for real world evidence generation and clinical trials
- Producing tangible benefits to health care organizations in a value-based model of care delivery
Mikhail N. Kosiborod, MD
Executive Director
Mikhail Kosiborod, MD, is a cardiologist, Vice President of Research at Saint Luke’s, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City School of Medicine, and the inaugural recipient of the Ben McCallister, MD, Endowed Chair in Cardiovascular Research at Saint Luke’s.
Dr. Kosiborod is an internationally recognized expert in the field of cardiometabolic disease and has authored and co-authored more than 400 peer-reviewed publications. Dr. Kosiborod has conducted and been involved in leadership of numerous national and international clinical trials, including DEFINE-HF, DAPA-HF, DELIVER, DARE-19, EMBRACE-HF, EMPULSE, PRESERVED-HF, REALIZE-K, and STEP-HFpEF. Many of his trials have had a significant impact on treatment guidelines and clinical practice. Dr. Kosiborod’s body of work has been central to the elucidation of the impact of sodium-glucose co-transporter-2 inhibition and GLP-1 receptor agonism in improving cardiovascular outcomes and survival in various clinical settings, perhaps some of the most important advances in clinical cardiology seen in a generation.
Melissa Magwire, RN, MSN, CDCES
Program Director
Melissa Magwire is a Master’s prepared Registered Nurse and Certified Diabetes Education and Care Specialist (CDCES) with more than 30 years of experience in the cardiovascular and diabetes care space. She provides direct patient care to those living with diabetes, focusing on cardiovascular risk reduction and is the Program Director for the Cardiometabolic Center Alliance, a national consortium of Cardiometabolic Centers of Excellence. She is a contributing author on the 2018 and 2020 ACC Expert Consensus Decision Pathway for CV Reduction in Patients with T2DM and ASCVD. She has authored over 20 peer reviewed publications, served on the Editorial Board of Clinical Diabetes, and is currently serving as a member of the ADCES Clinical Practice Committee, the AHA Council on Lifestyle and Cardiometabolic health Diabetes Science Committee as well as several national key opinion leader advisory boards.
Daniel Aistrope, PharmD, BCACP
Program Consultant
Angie Skinner
Program Consultant
Andrea Stafos, DNP, ANP-BC, BC-ADM
Program Consultant
Kyle Hamersley, RN, BSN
Program Consultant
Power in Numbers: Join Us
The Cardiometabolic Center Alliance is seeking to collaborate with health care organizations, academic and professional societies, and other key partners nationally and internationally in order to continue implementing this clinical model of care ensuring more patients receive comprehensive, coordinated cardiometabolic care and risk reduction.
Working collaboratively, we will lead an international initiative to significantly impact the toll of diabetes and related comorbidities. Together, we will help patients with cardiometabolic disease manage their risk factors so they can live healthier, more active lives, and help ease the burden on health care organizations caring for this complex patient population.
The Cardiometabolic Center Alliance provides its members with the training, protocols, and materials needed to establish their own cardiometabolic centers of excellence. The Alliance is committed to improving patient outcomes through improving processes and care delivery; measuring results; and expanding research opportunities on an international scale.